Moomoo AI 已提取核心訊息
Burning Rock Biotech Limited, a precision oncology company utilizing next generation sequencing technology, announced on January 4, 2024, that it received a notification from NASDAQ on December 29, 2023, regarding non-compliance with the minimum bid price requirement. For 30 consecutive business days, the closing bid price of the company's American depositary shares (ADSs) was below the required $1.00 per share. The NASDAQ notice does not currently affect the trading of Burning Rock's securities. The company has until June 26, 2024, to regain compliance with the minimum bid price rule, which can be achieved if its closing bid price reaches $1.00 for at least 10 consecutive business days during this period. If compliance is not met by the deadline, Burning Rock may be granted an additional 180 days to meet the requirement. The company's operations remain unaffected by this notice, and it plans to take reasonable measures to regain compliance. Burning Rock's business includes NGS-based therapy selection testing for late-stage cancer patients and NGS-based cancer early detection, which is in the clinical validation stage.
Burning Rock Biotech Limited, a precision oncology company utilizing next generation sequencing technology, announced on January 4, 2024, that it received a notification from NASDAQ on December 29, 2023, regarding non-compliance with the minimum bid price requirement. For 30 consecutive business days, the closing bid price of the company's American depositary shares (ADSs) was below the required $1.00 per share. The NASDAQ notice does not currently affect the trading of Burning Rock's securities. The company has until June 26, 2024, to regain compliance with the minimum bid price rule, which can be achieved if its closing bid price reaches $1.00 for at least 10 consecutive business days during this period. If compliance is not met by the deadline, Burning Rock may be granted an additional 180 days to meet the requirement. The company's operations remain unaffected by this notice, and it plans to take reasonable measures to regain compliance. Burning Rock's business includes NGS-based therapy selection testing for late-stage cancer patients and NGS-based cancer early detection, which is in the clinical validation stage.
使用下一代測序技術的精準腫瘤學公司Burning Rock Biotech Limited於2024年1月4日宣佈，它於2023年12月29日收到納斯達克關於未遵守最低出價要求的通知。連續30個工作日，該公司美國存托股票（ADS）的收盤價低於所需的每股1.00美元。納斯達克的通知目前並未影響Burning Rock證券的交易。該公司必須在2024年6月26日之前重新遵守最低出價規則，如果在此期間至少連續10個工作日的收盤出價達到1.00美元，則可以實現最低出價規則。如果在截止日期前未達到合規要求，Burning Rock可以再獲得180天的時間來滿足要求。該公司的運營不受本通知的影響，並計劃採取合理措施恢復合規性。Burning Rock的業務包括針對晚期癌症患者的基於NGS的療法選擇測試和基於NGS的癌症早期檢測，後者處於臨床驗證階段。
使用下一代測序技術的精準腫瘤學公司Burning Rock Biotech Limited於2024年1月4日宣佈，它於2023年12月29日收到納斯達克關於未遵守最低出價要求的通知。連續30個工作日，該公司美國存托股票（ADS）的收盤價低於所需的每股1.00美元。納斯達克的通知目前並未影響Burning Rock證券的交易。該公司必須在2024年6月26日之前重新遵守最低出價規則，如果在此期間至少連續10個工作日的收盤出價達到1.00美元，則可以實現最低出價規則。如果在截止日期前未達到合規要求，Burning Rock可以再獲得180天的時間來滿足要求。該公司的運營不受本通知的影響，並計劃採取合理措施恢復合規性。Burning Rock的業務包括針對晚期癌症患者的基於NGS的療法選擇測試和基於NGS的癌症早期檢測，後者處於臨床驗證階段。
有用
沒用